Endurant Capital Management’s Immunic IMUX Stock Holding History

Endurant Capital Management’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3,059	Closed	-$106K	–	59
2022 Q2	$106K	Sell	3,059 -9,998	-77%	-$641K	0.04%	50
2022 Q1	$1.48M	Sell	13,057 -5,397	-29%	-$625K	0.39%	46
2021 Q4	$1.77M	Sell	18,454 -91	-0.5%	-$8.2K	0.43%	43
2021 Q3	$1.64M	Buy	18,545 +830	+5%	+$81.7K	0.37%	44
2021 Q2	$2.17M	Buy	17,715 +4,535	+34%	+$627K	0.6%	45
2021 Q1	$2.1M	Sell	13,180 -681	-5%	-$116K	0.55%	49
2020 Q4	$2.12M	Buy	13,861 +2,770	+25%	+$497K	0.76%	39
2020 Q3	$2.06M	Buy	+11,091	New	+$1.82M	0.61%	43

Other funds holding IMUX

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Gratus Capital Atlanta, Georgia $2.5B AUM 32.89% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Endurant Capital Management's IMUX Position: Q3 2022 in Review

Endurant Capital Management sold out of Immunic (IMUX) in Q3 2022, closing a stake of 3,059 shares — an estimated $106K sold.

Endurant Capital Management first reported a position in IMUX in Q3 2020 and held it in 8 quarters. The position peaked at $2.17M in Q2 2021. 65 funds tracked by Wall St. Rank hold IMUX as of Q3 2022.

Endurant Capital Management reported no remaining Immunic position as of Q3 2022 after selling out during the quarter.
Endurant Capital Management sold 3,059 Immunic shares in Q3 2022, an estimated $106K.
Endurant Capital Management first reported a position in Immunic in Q3 2020 and held it in 8 quarters.
Endurant Capital Management's Immunic position peaked at $2.17M in Q2 2021.
65 funds tracked by Wall St. Rank held Immunic as of Q3 2022.

Based on Endurant Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.